Elevated levels of TLE1 have been observed in a growing list of tumours, including cervical, lung and colon carcinomas, and TLE1 has been recognised as a putative oncogene.2 Given that TLE1 does not bind to DNA directly, and that its repressive and potentially oncogenic role relies on the ability of the WDR domain to bind to transcription factors, blocking of this interaction has been suggested as a possible treatment for cancers with elevated TLE1 activity.3 However, to date, no TLE inhibitors have been described in the literature. The gene discussed is TLE1; the disease is cancer.